M
Michael A. Matthay
Researcher at University of California, San Francisco
Publications - 1063
Citations - 110857
Michael A. Matthay is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung injury & Lung. The author has an hindex of 151, co-authored 998 publications receiving 98687 citations. Previous affiliations of Michael A. Matthay include University of California & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Early expression of β- and γ-subunits of epithelial sodium channel during human airway development
Dominique Gaillard,Jocelyne Hinnrasky,Sylvie Coscoy,Paul Hofman,Michael A. Matthay,Edith Puchelle,Pascal Barbry,Pascal Barbry +7 more
TL;DR: The amiloride-sensitive epithelial Na+channel (ENaC) is an apical membrane protein complex involved in active Na+ absorption and in control of fluid composition in airways.
Journal ArticleDOI
Applying metabolomics to uncover novel biology in ARDS
TL;DR: It is proposed that new studies that measure the chemical breakdown products of cellular metabolism (metabolomics) may provide new insights into ARDS, in part because metabolomics targets a later point in the genomics cascade than is possible with studies of DNA, RNA, and protein biomarkers.
Book ChapterDOI
Transepithelial sodium and water transport in the lung
TL;DR: In this article, the authors show that pharmacological treatment with beta-adrenergic agonists and/or epithelial growth factors may induce a more sustained stimulation of alveolar fluid reabsorption and in turn facilitate recovery from experimental pulmonary edema.
Journal ArticleDOI
Neutrophil-activating peptide-2 in patients with pulmonary edema from congestive heart failure or ARDS.
A. B. Cohen,M. D. Stevens,E. J. Miller,M. A. L. Atkinson,G. Mullenbach,R. J. Maunder,T. R. Martin,Jeanine P. Wiener-Kronish,Michael A. Matthay +8 more
TL;DR: Data suggest that significant platelet degranulation occurred into the lungs of the patients with CHF and that NAP-2 and other platelet constituents may contribute to fluid formation in patients withCHF.
Journal ArticleDOI
Possible hepatotoxicity of IQOS.
TL;DR: The preclinical and clinical data PMI submitted to FDA indicate that IQOS exposure may be associated with unexpected liver toxicity, and PMI’s Modified Risk Tobacco Product application submitted to the US FDA is indicated.